stock
OCUL · OCULAR THERAPEUTIX, INC
What OCULAR THERAPEUTIX, INC reports to the SEC, read from its filings.
Open in the appPrice
The live OCUL price and today's change.
Sign in to see thisChart
Thirty days of daily bars, with signal levels drawn on them.
Sign in to see thisSignals
The latest signal group Nakagai's scanner recorded on OCUL.
Sign in to see thisOptions positioning
Gamma exposure levels from the options market.
Sign in to see thisTechnicals
Trend, momentum and volatility gauges per timeframe.
Sign in to see thisWhat it is
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Filer (SEC EDGAR)
- EDGAR filing index
- Shares outstanding
- 219,615,868 as of 2026-07-31 (XBRL frame CY2026Q2I)
Key stats
Valuation
- P/E
- Locked
- P/S
- Locked
- P/B
- Locked
- Enterprise value
- Locked
- EV/EBIT
- Locked
- FCF yield
- Locked
Margins
- Gross
- —
- Operating
- -603.0%
- Net
- -579.1%
Returns
- ROE
- -58.0%
- ROA
- -44.9%
Health
- Current ratio
- 13.1x
- Debt/equity
- —
Deep value
- NCAV
- $493.15M
- NCAV per share
- $2.25
- Price/NCAV
- Locked
- NNWC
- $471.97M
- NNWC per share
- $2.15
- Price/NNWC
- Locked
Valuation and the price multiples are built on the live price. Trailing twelve months to 2026-06-30; balance sheet at 2026-06-30.
Sign in to see thisDebt is long-term debt and its current portion. Commercial paper and short-term borrowings are not counted.
Results
| Period end | Revenue | Gross profit (not reported by this company) | Operating income | Net income | Filing |
|---|---|---|---|---|---|
| 2026-06-30 | $13.47M | —Gross profit: unreported by this company. | -$82.11M | -$78.76M | 10-Q filed 2026-08-03 |
| 2026-03-31 | $10.79M | —Gross profit: unreported by this company. | -$93.34M | -$88.61M | 10-Q filed 2026-08-03 Assembled from more than one filing; the filing above is only the newest of them. |
| 2025-12-31 | $13.25M | —Gross profit: unreported by this company. | -$69.76M | -$64.65M | DEF 14A filed 2026-04-30 Derived: the full year minus the first three quarters, not a figure this filer reported as a quarter. Assembled from more than one filing; the filing above is only the newest of them. |
| 2025-09-30 | $14.54M | —Gross profit: unreported by this company. | -$68.70M | -$69.42M | 10-Q filed 2025-11-04 |
| 2025-06-30 | $13.46M | —Gross profit: unreported by this company. | -$67.64M | -$67.81M | 10-Q filed 2026-08-03 |
| 2025-03-31 | $10.70M | —Gross profit: unreported by this company. | -$63.92M | -$64.05M | 10-Q filed 2026-08-03 Assembled from more than one filing; the filing above is only the newest of them. |
| 2024-12-31 | $17.08M | —Gross profit: unreported by this company. | -$50.58M | -$48.39M | DEF 14A filed 2026-04-30 Derived: the full year minus the first three quarters, not a figure this filer reported as a quarter. Assembled from more than one filing; the filing above is only the newest of them. |
| 2024-09-30 | $15.43M | —Gross profit: unreported by this company. | -$46.00M | -$36.49M | 10-Q filed 2025-11-04 |
- Assets
- $671.32M
- Equity
- $520.04M
Balance as of 2026-06-30.
Ten years
| Fiscal year end | Revenue | Operating income | Net income | Free cash flow |
|---|---|---|---|---|
| 2025-12-31 | $51.95M | -$270.02M | -$265.94M | -$216.89M |
| 2024-12-31 | $63.72M | -$171.78M | -$193.51M | -$135.97M |
| 2023-12-31 | $58.44M | -$82.38M | -$80.74M | -$76.32M |
| 2022-12-31 | $51.49M | -$78.65M | -$71.04M | -$63.32M |
| 2021-12-31 | $43.52M | -$78.04M | -$6.55M | -$66.74M |
| 2020-12-31 | $17.40M | -$62.85M | -$155.64M | -$54.40M |
| 2019-12-31 | $4.23M | -$85.80M | -$86.37M | -$79.82M |
| 2018-12-31 | $1.99M | -$59.12M | -$59.98M | -$51.12M |
| 2017-12-31 | $1.92M | -$61.92M | -$63.39M | -$58.73M |
| 2016-12-31 | $1.89M | -$43.33M | -$44.70M | -$35.92M |
Company filings
events
Results
ResultsAug 38-KExecutive or director change, Shareholder vote results
Executive or director changeShareholder vote resultsJun 128-KResults
ResultsMay 58-KRegulation FD disclosure
Regulation FD disclosureFeb 278-KResults
ResultsFeb 58-KExecutive or director change
Executive or director changeJan 238-K
5% owners ()
BlackRock, Inc.
Stake update
Deep Track Capital, LP
Stake update
The Vanguard Group
Stake update
Venrock Healthcare Capital Partners III, L.P.
Stake update
Deep Track Capital, LP
Passive stake
Insiders, politicians and funds
Insider trades, last 90 days
Notman Donald
Chief Operating Officer
Sale$11,254Sep 2, 4:01 PM ET
Kaiser Peter
Chief Development Officer
Sale$32,687Aug 26, 5:59 PM ET
Nayak Sanjay
Chief Strategy Officer
Sale$20,450Aug 26, 5:58 PM ET
Heier Jeffrey S.
Chief Scientific Officer
Sale$35,531Aug 26, 5:57 PM ET
Dugel Pravin
See Remarks, Director
Sale$233,160Aug 26, 5:56 PM ET
Politician trades, last 90 days
No politician trades filed in the last 90 days.
News
Stories that named OCUL, and the market events around them.
Sign in to see thisBoard
Recent signals
Signals open up here once a member has posted about OCUL.
Signals are informational.
Posts · 0
No posts yet.
nakagai
Signals on OCUL come from a rule, not a model.
Nakagai’s scanner records a signal the moment a strategy’s rule matches on the bars. Members read those signals on their own desk, where an agent journals the tape and briefs them in plain English.
Members post on the OCUL board